Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model

Vaccine

Volumn 22, Issue 13-14, 2004, Pages 1782-1790

  Otero, Miguel ^a   Calarota, Sandra A ^a   Felber, Barbara ^a   Laddy, Dominic ^a   Pavlakis, George ^a   Boyer, Jean D ^a   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

HIV 1; Immunization; Resiquimod

Indexed keywords

DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; INTERLEUKIN 4; RESIQUIMOD;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; T LYMPHOCYTE; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; GENE PRODUCTS, GAG; HIV ANTIBODIES; IMIDAZOLES; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INTERFERON TYPE II; LYMPHOCYTE COUNT; MICE; MICE, INBRED BALB C; PLASMIDS; VACCINES, DNA;

EID: 1842578532     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.01.037     Document Type: Article

References (50)

1. Wahren B. Gene vaccines. Immunotechnology. 2(2):1996;77-83.
2. Chattergoon M., Boyer J., Weiner D.B. Genetic immunization: a new era in vaccines and immune therapeutics. FASEB J. 11(10):1997;753-763.
3. Davis H.L., McCluskie M.J. DNA vaccines for viral diseases. Microbe Infect. 1(1):1999;7-21.
4. http://www.grouppekurosawa.com.
5. Schirmbeck R., Reimann J. Revealing the potential of DNA-based vaccination: lessons learned from the hepatitis B virus surface antigen. Biol. Chem. 382(4):2001;543-552.
6. Bagarazzi M.L.et al. Safety and immunogenicity of intramuscular and intravaginal delivery of HIV-1 DNA constructs to infant chimpanzees. J. Med. Primatol. 26(1-2):1997;27-33.
7. Ugen K.E.et al. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine. 16(19):1998;1818-1821.
8. Bagarazzi M.L.et al. Safety and immunogenicity of HIV-1 DNA constructs in chimpanzees. Vaccine. 16(19):1998;1836-1841.
9. MacGregor R.R.et al. T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev. AIDS. 16(16):2002;2137-2143.
10. MacGregor R.R., Ugen B.J., Gluckman K.E., Bagarazzi S.J., Chatergoon M.L., Baine M.A.et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J. Infect. Dis. 178(1):1998;92-100.
11. Calarota S.et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet. 351(9112):1998;1320-1325.
12. Paroli M.et al. The immunology of HIV-infected long-term non-progressors: a current view. Immunol. Lett. 79(1-2):2001;127-129.
13. Clerici M., Shearer G.M. Correlates of protection in HIV infection and the progression of HIV infection to AIDS. Immunol. Lett. 51(1-2):1996;69-73.
14. Palella FJ, Delaney K.M., Moorman A.C. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998:338/13; 853-60.
15. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trial Group 320 Study Team. N Engl J Med 1997:337;725-33.
16. Ross R.W., Wright M.E., Tavel J.A. Ongoing trials of immune-based therapies for HIV infection in adults. Expert Opin. Biol. Ther. 1(3):2001;413-424.
17. Siliciano J.D., Finzi K.J., Quinn D., Chadwick T.C., Margolick K., Kovacs J.B.et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4(+) T cells. Nat. Med. 9(6):2003;727-728.
18. Nunez M, AR, Valencia ME, et al. Rate, causes and clinical implications of presenting with low CD4(+) cell counts in the era of highly active antiretroviral thereapy. AIDS Res Hum Retroviruses 2003:19;363-8.
19. Saksena NK, HD. Viral reservoirs an impediment to HAART: new strategies to eliminate HIV-1. Curr Drug Targets Infect Disord 2003:3;179-206.
20. Pachuk C.J.et al. Characterization of a new class of DNA delivery complexes formed by the local anesthetic bupivacaine. Biochim. Biophys. Acta. 1468(1-2):2000;20-30.
21. Berinstein A., Sadir A.M. Adjuvants: updates on concepts. Revista Argentina de Microbiologia. 22(3):1990;159-166.
22. Lise L.D., Audibert F. Immunoadjuvants and analogs of immunomodulatory bacterial structures. Curr. Opin. Immunol. 2(2):1989;269-274.
23. O'Hagan D.T., Lavelle E. Novel adjuvants and delivery systems for HIV vaccines. AIDS. 16(Suppl 4):2002;S115-S124.
24. Boyer J.D.et al. Next generation DNA vaccines for HIV-1. J Liposome Res. 12(1-2):2002;137-142.
25. O'Hagan D.T., MacKichan M.L., Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng. 18(3):2001;69-85.
26. Sasaki S.et al. The search for a potent DNA vaccine against AIDS: the enhancement of immunogenicity by chemical and genetic adjuvants. Anticancer Res. 18(5D):1998;3907-3915.
27. Singh M., O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol. 17(11):1999;1075-1081.
28. Velin D., Kraehenbuhl J.P. Delivery systems and adjuvants for vaccination against HIV. EXS. 89:2000;227-237.
29. Mahon B.P. The rational design of vaccine adjuvants for mucosal and neonatal immunization. Curr Med Chem. 8(9):2001;1057-1075.
30. Scheerlinck J.Y. Genetic adjuvants for DNA vaccines. Vaccine. 19(17-19):2001;2647-2656.
31. Pasquini S.et al. Cytokines and costimulatory molecules as genetic adjuvants. Immunol. Cell Biol. 75(4):1997;397-401.
32. Boraschi D., Tagliabue A. Interleukin-1 and interleukin-1 fragments as vaccine adjuvants. Methods. 19(1):1999;108-113.
33. Sin J.I.et al. Engineering of DNA vaccines using molecular adjuvant plasmids. Dev. Biol. 104:2000;187-198.
34. Leitner W.W., Hammerl P., Thalhamer J. Nucleic acid for the treatment of cancer: genetic vaccines and DNA adjuvants. Curr. Pharm. Des. 7(16):2001;1641-1667.
35. Brugnolo F.et al. The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells. J. Allergy Clin. Immunol. 111(2):2003;380-388.
36. Miller R.L.et al. Immunomodulation as a treatment strategy for genital herpes: review of the evidence. Int. Immunopharmacol. 2(4):2002;443-451.
37. Hemmi H., Kaisho O., Sato S., Sanjo H., Hoshino K., Horiuchi T.et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3(2):2002;196-200.
38. Skinner RB, J. Imiquimod. Dermatol Clin 2003:21;291-300.
39. Stanley M.A. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. 27(7):2002;571-577.
40. Berman B., Poochareon V.N., Villa A.M. Novel dermatologic uses of the immune response modifier imiquimod 5% cream. Skin Ther. Lett. 7(9):2002;1-6.
41. Qiu J.T.et al. Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses. J. Virol. 73(11):1999;9145-9152.
42. Pachuk C.J.et al. DNA vaccines-challenges in delivery. Curr. Opin. Mol. Ther. 2(2):2000;188-198.
43. Zhu M.et al. Enhancement of DNA vaccine potency against herpes simplex virus 1 by co-administration of an interleukin-18 expression plasmid as a genetic adjuvant. J. Med. Microbiol. 52(Pt 3):2003;223-228.
44. Du D.W.et al. HBV DNA vaccine with adjuvant cytokines induced specific immune responses against HBV infection. World J. Gastroenterol. 9(1):2003;108-111.
45. Lena P.et al. Co-immunization of rhesus macaques with plasmid vectors expressing IFN-gamma, GM-CSF, and SIV antigens enhances anti-viral humoral immunity but does not affect viremia after challenge with highly pathogenic virus. Vaccine. 20(Suppl 4):2002;A69-A79.
46. Sun X.et al. Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination. Vaccine. 20(9-10):2002;1466-1474.
47. Min W.et al. Adjuvant effects of IL-1beta, IL-2, IL-8, IL-15, IFN-alpha, IFN-gamma TGF-beta4 and lymphotactin on DNA vaccination against Eimeria acervulina. Vaccine. 20(1-2):2001;267-274.
48. Moore A.C.et al. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J. Virol. 76(1):2002;243-250.
49. Ko K.S.et al. Combined administration of plasmids encoding IL-4 and IL-10 prevents the development of autoimmune diabetes in nonobese diabetic mice. Mol. Ther. J Am. Soc.Gene Ther. 4(4):2001;313-316.
50. Eo S.K.et al. Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands. Vaccine. 19(32):2001;4685-4693.